Christelle Clément-Duchêne
YOU?
Author Swipe
View article: Data from Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
Data from Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study Open
Purpose: The phase II prospective, noncomparative BRAIN study (NCT00800202) investigated efficacy and safety of bevacizumab in chemotherapy-naïve or pretreated patients with non–small cell lung cancer (NSCLC) and asymptomatic untreated bra…
View article: Appendix Methods and Materials, Tables 1-4, Figures 1-3 from Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
Appendix Methods and Materials, Tables 1-4, Figures 1-3 from Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study Open
Appendix Methods and Materials, Tables 1-4, Figures 1-3. Appendix Table 1: Characteristics of patients at baseline Appendix Table 2: Best response rates for primary tumors and metastases in 24 patients treated with second-line bevacizumab …
View article: Supplementary Table S1 from Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
Supplementary Table S1 from Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study Open
Supplementary Table S1: Best response rates for primary tumors and metastases in 67 patients (ITT population) treated with bevacizumab plus paclitaxel and carboplatin
View article: Supplementary Table S1 from Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
Supplementary Table S1 from Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study Open
Supplementary Table S1: Best response rates for primary tumors and metastases in 67 patients (ITT population) treated with bevacizumab plus paclitaxel and carboplatin
View article: Data from Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
Data from Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study Open
Purpose: The phase II prospective, noncomparative BRAIN study (NCT00800202) investigated efficacy and safety of bevacizumab in chemotherapy-naïve or pretreated patients with non–small cell lung cancer (NSCLC) and asymptomatic untreated bra…
View article: Appendix Methods and Materials, Tables 1-4, Figures 1-3 from Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
Appendix Methods and Materials, Tables 1-4, Figures 1-3 from Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study Open
Appendix Methods and Materials, Tables 1-4, Figures 1-3. Appendix Table 1: Characteristics of patients at baseline Appendix Table 2: Best response rates for primary tumors and metastases in 24 patients treated with second-line bevacizumab …
Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors Open
Background The use of antibiotics (ATB) and proton-pump inhibitors (PPI) alters the composition and diversity of the gut microbiota, which can influence the immune system, consequently interfering with response to anti-PD1 immune checkpoin…
Survival in surgical non-small cell lung cancer in a French Hospital Open
Introduction.La stadification du cancer du poumon avec tomographie par émission de positrons et les traitements adjuvants (TA) ont été progressivement utilisés pour la gestion du cancer du poumon non à petites cellules (CBNPC) chirurgical.…
A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy Open
Our study adds further evidence of safety of administering pemetrexed and bevacizumab to patients with stable brain metastases. There is increasing roles for systemic therapies to treat stable brain metastases for patients with advanced NS…
AB004. OS01.04. Prevalence of autoimmune diseases in thymic epithelial tumors insights from RYTHMIC Open
Background: Thymic epithelial tumor (TET) has been associated with autoimmune disorders (AID) in up to 30% of patients. However, there have been wide variations in the reported prevalence of TET associated disorders based mostly on small s…